Liberati, D., Wyatt, R. C., Brigatti, C., Marzinotto, I., Ferrari, M., Bazzigaluppi, E., Bosi, E., Gillard, B. T., Gillespie, K. M., Gorus, F., Weets, I., Balti, E., Piemonti, L., Achenbach, P., Williams, A. J. K., & Lampasona, V. (2018). A novel LIPS assay for insulin autoantibodies. *Acta Diabetologica*, 55, 263-270. <https://doi.org/10.1007/s00592-017-1082-y>

Peer reviewed version

Link to published version (if available):

[10.1007/s00592-017-1082-y](https://doi.org/10.1007/s00592-017-1082-y)

[Link to publication record in Explore Bristol Research](#)

PDF-document

This is the author accepted manuscript (AAM). The final published version (version of record) is available online via Springer at <https://link.springer.com/article/10.1007%2Fs00592-017-1082-y>. Please refer to any applicable terms of use of the publisher.

University of Bristol - Explore Bristol Research

General rights

This document is made available in accordance with publisher policies. Please cite only the published version using the reference above. Full terms of use are available: <http://www.bristol.ac.uk/red/research-policy/pure/user-guides/ebr-terms/>

Acta Diabetologica

A novel LIPS assay for insulin autoantibodies

--Manuscript Draft--

Manuscript Number:	ACDI-D-17-00425R1	
Full Title:	A novel LIPS assay for insulin autoantibodies	
Article Type:	Original Article	
Corresponding Author:	Vito Lampasona IRCCS San Raffaele Scientific Institute ITALY	
Corresponding Author Secondary Information:		
Corresponding Author's Institution:	IRCCS San Raffaele Scientific Institute	
Corresponding Author's Secondary Institution:		
First Author:	Daniela Liberati	
First Author Secondary Information:		
Order of Authors:	Daniela Liberati	
	Rebecca Wyatt	
	Cristina Brigatti	
	Ilaria Marzinotto	
	Maurizio Ferrari	
	Elena Bazzigaluppi	
	Emanuele Bosi	
	Ben Gillard	
	Kathleen Gillespie	
	Frans Gorus	
	Ilse Weets	
	Eric Balti	
	Lorenzo Piemonti	
	Peter Achenbach	
	Alistair Williams	
	Vito Lampasona	
Order of Authors Secondary Information:		
Funding Information:	JDRF (2-SRA-2015-50-Q-R)	Prof. Lorenzo Piemonti
	Leona M. and Harry B. Helmsley Charitable Trust (2-SRA-2015-50-Q-R)	Prof. Lorenzo Piemonti
	Fonds Wetenschappelijk Onderzoek (G.0868.11)	Prof. Frans Gorus
	Vrije Universiteit Brussel (SRP-42)	Prof. Frans Gorus
	Willy Gepts Fund of Universitair Ziekenhuis Brussel (G177/2013)	Prof. Frans Gorus

	Flemish Government project (IWT 130138)	Prof. Frans Gorus
Abstract:	<p>Aims. Insulin autoantibodies (IAA) are often the first marker of autoimmunity detected in children in the pre-clinical phase of type 1 diabetes (T1D). Currently, the vast majority of laboratories adopt the radiobinding micro-assay (RBA) for measuring IAA. Our aim was to replace RBA with a novel non-radioactive IAA Luciferase Immuno Precipitation System (LIPS) assay with improved performance.</p> <p>Methods. We developed (pro)insulins antigens with alternative placements of a NanoLuc luciferase reporter (NLuc). Performance in LIPS was evaluated by testing sera from new onset T1D (n=80), blood donors (n=123), schoolchildren (n=186), first degree relatives (FDRs) from the Bart's Oxford family study (n=53) and from the Belgian Diabetes Registry (n=136), coded sera from the Islet Autoantibody Standardization Program (IASP) (T1D n=50, blood donors n=90).</p> <p>Results. IAA LIPS based on B chain-NLuc proinsulin or B chain-NLuc insulin, in which NLuc was fused at the C-terminus of the insulin B chain, required only 2 µL of serum and a short incubation time, showed high concordance with RBA (Spearman $r = 0.866$ and 0.833, respectively), high assay performance (B chain-NLuc proinsulin ROC-AUC = 0.894 and B chain-NLuc insulin ROC-AUC=0.916), and an adjusted sensitivity at 95% specificity ranking on par with the best assays submitted to the two most recent IASP workshops. In FDRs, the IAA LIPS showed improved discrimination of progressors to T1D compared to RBA.</p> <p>Conclusions. We established a novel high performance non-radioactive IAA LIPS that might replace the current gold standard RBA and find wide application in the study of the IAA response in T1D.</p>	
Response to Reviewers:	<p>We thank the reviewers for their positive comments and useful suggestions. Please find below our point to point response to the reviewers' requests:</p> <p>Reviewer #1: "In my point of view of a reader not necessary technical i think that the part of the result must be shortened and focused in particular page 5 and 6." We have now revised this section to make it more synthetic and hopefully clearer.</p> <p>Reviewer #3: "Abstractthere is conflicting data which indicates that the Spearman r value quoted as $r=0.9778$ refers to correlation between LIPS and not between LIPS and RBA (which is either $r=0.866$ (B chain-NLuc proinsulin/RBA) or $r=0.8331$ (B chain-NLuc proinsulin/RBA))" We stand corrected, we have now indicated in the abstract the two Spearman r correlations for the B chain-NLuc proinsulin and insulin LIPS assays in comparison to RBA, respectively.</p> <p>"Introduction (Page 3 line 12): I believe this should read "enrolling children" rather than "enroll children". " This has now been fixed in the text</p> <p>"Material and Methods (Page 4 line 8-9): the 50 new onset T1D patients and 90 blood donor controls coded samples and from the 2015-2016 IASP workshops do not appear in the summary table 1 of the ESM." The IASP samples have now been added in the ESM Table</p> <p>"Section 2.3and the luciferase activity measured using in the luminometer by injecting each well...." The sentence has been modified in the text</p> <p>"Could the concordance for B chain-NLuc insulin LIPS be also shown or alternatively the paragraph on page 7 (from line 33) be adjusted to indicate that the figures quoted only refer to proinsulin." We fixed the sentence in the text clarifying that the comparison refers to just the B chain-NLuc proinsulin LIPS</p> <p>"Figure Legends page 17 line 13. For clarity I think there should be punctuation within....the section "C-peptide (black line) dashed line"</p>	

	The legend has been fixed as suggested.
--	---

[Click here to view linked References](#)

A novel LIPS assay for insulin autoantibodies

Daniela Liberati^{a-b*}, Rebecca Wyatt^{c*}, Cristina Brigatti^b, Ilaria Marzinotto^b, Maurizio Ferrari^{a,e},
Elena Bazzigaluppi^d, Emanuele Bosi^{b,e}, Ben Gillard^c, Kathleen Gillespie^c, Frans Gorus^{f,g}, Ilse
Weets^{f,g}, Eric Balti^{f,g}, Lorenzo Piemonti^{b,e}, Peter Achenbach^h, Alistair Williams^c, Vito
Lampasona^a

^aDivision of Genetics and Cell Biology, IRCCS San Raffaele Scientific Institute, Milan, Italy

^bDiabetes Research Institute, IRCCS San Raffaele Scientific Institute, Milan, Italy

^cTranslational Health Sciences, University of Bristol, Bristol, UK;

^dDepartment of Laboratory Medicine, IRCCS San Raffaele Scientific Institute, Milan, Italy

^eVita-Salute San Raffaele University, Milan, Italy

^fDiabetes Research Center, Vrije Universiteit, Brussel, Brussels, Belgium

^gDepartment of Clinical Chemistry, Universitair Ziekenhuis Brussel, Brussels, Belgium

^hInstitute of Diabetes Research, Helmholtz Zentrum München, and Forschergruppe Diabetes, Klinikum rechts der Isar, Technische Universität München, Neuherberg, Germany

*These authors contributed equally

Corresponding author:

Vito Lampasona, Human Pathology Genomic Diagnostics unit, Division of Genetics and Cell Biology, Via Olgettina 60, 20132 Milano, Italy, Phone: 0390226432540, Fax: 0390226434351, e-mail: lampasona.vito@hsr.it ORCID: orcid.org/0000-0001-5162-8445

Keywords

Insulin; autoantibodies; T1D; immunoassay; LIPS; prediction

Acknowledgments

This study was supported by the JDRF- The Leona M. and Harry B. Helmsley Charitable Trust grant 2-SRA-2015-50-Q-R. The study was conducted within the framework of the Italian Ministry of Research's project "Ivascomar project, Cluster Tecnologico Nazionale Scienze della Vita ALISEI". The Belgian Diabetes Registry is supported by the Research Foundation-Flanders

(Fonds Wetenschappelijk Onderzoek-Vlaanderen) project nr. G.0868.11, the Research Council of the Vrije Universiteit Brussel project SRP-42, the Willy Gepts Fund of Universitair Ziekenhuis Brussel project G177/2013, and the Flemish Government project IWT 130138.

Abbreviations

IAA, Insulin autoantibodies; T1D, type 1 diabetes; FDR, first degree relative; RBA, radiobinding micro-assay; LIPS, Luciferase Immuno Precipitation System; BOX study, Bart's-Oxford study; BDR, Belgian Diabetes Registry BDR; IASP, Islet Autoantibodies Standardization Program; ROC-AUC, area under the Receiver Operator Curve; AS95, adjusted sensitivity at 95% specificity; NLuc, nanoluc luciferase; sNLuc, secretory nanoluc luciferase; LU, light units; AU, arbitrary units.

1. Introduction

Insulin autoantibodies (IAA) [1] are frequently the first autoantibodies detected in children in the pre-clinical phase of type 1 diabetes (T1D) [2]. Therefore, IAA measurement is a cornerstone of the study of the T1D natural history [3–5] and of all screening strategies aimed at identifying and enrolling children at increased T1D risk in prevention trials [6]. Currently, the vast majority of laboratories measuring IAA adopt the radiobinding micro-assay (RBA), based on the immunoprecipitation of radiolabeled ¹²⁵I-insulin with patient serum [7, 8]. While years of effort, including several international standardization workshops, have led to assay improvements [9–13], compared with assays measuring other T1D autoantibodies, the IAA RBA shows lower concordance and reproducibility across laboratories, requires more serum and a lengthy incubation, and is critically dependent on a limited number of suppliers for the provision of radiolabeled tracer. Furthermore, a significant fraction of subjects identified as single IAA positive by RBA during screening do not progress to T1D, suggesting an imperfect discrimination of IAA responses truly correlated with disease progression [14].

Currently, novel IAA assays that aim to replace RBA are under active development, of which the most mature example is an ECL method [15–17]. In particular, most efforts are aimed at substituting radiolabeled tracers with non-radioactive and more stable antigens, reducing serum consumption and assay duration, while at the same time improving assay sensitivity, specificity, and prediction of future disease development [16, 18]. In this study, we report the development of a novel IAA assay based on the Luciferase Immuno Precipitation System (LIPS) [19–24], a format in which luciferase tagged antigens are immunoprecipitated with test sera, aimed at retaining most features of the classical IAA RBA while avoiding its shortcomings.

Material and methods

2.1 Study subjects

All procedures performed in the study involving human participants were in accordance with the ethical standards of the institutional and/or national research committee and with the 1964 Helsinki declaration and its later amendments. Informed consent was obtained from all individual participants included in the study. Samples (ESM Table 1) included 80 new onset T1D patients and 123 blood donors from the San Raffaele Scientific Institute; 186 non-diabetic schoolchildren

1
2
3
4 and 53 non-diabetic first-degree relatives (FDRs) of patients with T1D, from the Bart's Oxford
5 (BOX) study [25]; 136 non-diabetic FDRs from the Belgian Diabetes Registry (BDR) family study
6 [26]; 50 new onset T1D patients and 90 blood donor controls coded samples from the 2015 and
7
8 2016 Islet Autoantibody Standardization Program (IASP) workshops.
9

10 11 12 **2.2 Recombinant luciferase tagged antigens production** 13

14 Custom synthetic genes (Eurofins Genomics GmbH, Munich, Germany) of recombinant proinsulin
15 or insulin antigens tagged with a NanoLuc™ (NLuc) luciferase reporter (Promega, Madison WI,
16 USA) were sub-cloned into a modified pCMVTNT™ vector (Promega). To express luciferase-
17 tagged insulins, PC1/2 convertases recognition sites were replaced with those of furin convertases
18 [27–29], allowing for cleavage of the C-peptide. Antigens were expressed by transfection into
19 Expi293F™ cells (Expi293™ Expression System, Thermo Fisher Scientific-Life Technologies,
20 Carlsbad, CA, USA). After 48 hours, cells were removed by centrifugation and the culture medium
21 harvested stored frozen at -80°C as single use aliquots. The recovered luciferase activity was
22 quantified by seeding the wells of an OptiPlate™ 96well plate (Perkin-Elmer, Waltham, MA,
23 USA) with 25 µL aliquots of serial tenfold dilutions of the antigen in 50mM tris buffer, 1% Tween-
24 20, pH 8 (TBT) followed by the addition of 40 µL of Nano-Glo® substrate (Promega), mixing and
25 measurement of light units (LU) bioluminescence for 2 seconds/ well in a Berthold Centro XS3
26 luminometer (Berthold Technologies GmbH & Co. KG, Bad Wildbad, Germany).
27
28
29
30
31
32
33
34
35
36
37
38

39 **2.3 IAA LIPS assay** 40

41 Antigens were diluted with TBT and luciferase activity adjusted to achieve a final concentration
42 of 10⁷ LU/25 µL, and then filtered with Durapore™ PVDF 0.45 µm Millex-HV syringe filter
43 (Millipore, Billerica, MA, USA). Immunoprecipitation was performed with and without
44 competition of IAA binding using ACTRAPID® insulin (Novo Nordisk, Bagsværd, Denmark)
45 added at a final concentration of 4.5x10⁻⁵ mol/L.
46
47
48
49

50
51 Four 2 µL replicates of each serum were pipetted into 96 Deep-well plates (Beckman Coulter Inc.,
52 Brea, CA, USA), 25 µL of antigen w/o competitor was added to half of the replicates, while the
53 rest received antigen plus competitor. Plates were then mixed briefly on a rotary shaker,
54 centrifuged for 2' at 500g at 4°C, and incubated for 24 hours at 4°C. Immunocomplexes were
55 captured by incubation with 5 µL of blocked [12] rProtein A and 2.5 µL of G sepharose 4Fast
56
57
58
59
60
61
62
63
64
65

Flow in 50 μ L TBT (GE Healthcare Europe GmbH, Freiburg, Germany), for 1 hour at 4°C, with shaking. Plates were washed 5 times by sequential dispensing of 750 μ L of TBT per well, centrifugation at 500g for 2' at 4°C, and removal of supernatant using a microplate plate washer (BioTek Instruments Inc., Winooski, VT, USA). Resin pellets were then transferred to an OptiPlate™, and the luciferase activity measured after addition of each well with 40 μ L of Nano-Glo® substrate, followed by a 2'' readout in the luminometer.

Acquired LU were converted to arbitrary units (AU) using a standard curve constructed from nine doubling dilutions in normal human serum of either a IAA positive serum or the monoclonal antibody HUI018 (Dako, Glostrup, Denmark), whose epitope is centered against the A chain loop of human insulin [30]. AU were calculated based on the delta of measured LU between competed and non-competed wells, using a logarithmic curve fitting algorithm in Excel (Microsoft Corporation, Redmond, WA, USA). All samples in which LU of non-competed replicates were below those of competed replicates were given a fixed value of 0.01 AU. The anti C-peptide monoclonal antibody C-PEP-01 (Santa Cruz Biotechnology, Inc. Dallas, TX, U.S.A.), directed against an epitope within the central part of the C-peptide [31], was used to check presence or absence of the C-peptide in the labelled antigen.

2.4 Statistical analysis

Statistical analysis was performed using the Prism v6 software (GraphPad Software, Inc., La Jolla CA, USA) and the pROC package for the R software [32, 33]. The area under the receiver operating characteristic (ROC) curve was used to verify the ability of the IAA LIPS test to discriminate cases from controls. Concordance of quantitative results of assays was assessed by calculating the Spearman's r correlation coefficient. Survival curves following Kaplan-Meier analysis were compared using the Mantel-Haenszel Log-Rank test.

Results

Expression and immunoprecipitation of (pro)insulin-luciferases

We generated and expressed in eukaryotic cells as secreted recombinant proteins eight different (pro)insulin-luciferase constructs in which NLuc reporter was placed either at the NH2 or COOH termini of the insulin A or B chains (Fig. 1). We evaluated, by immunoprecipitation, antibody binding to each of the expressed (pro)insulin-luciferases using serial dilutions of the HUI-018 mAb

(against a conformational epitope in the insulin A chain), the C-PEP01 mAb (against an epitope in the C-peptide), and two human sera, IAA positive and negative respectively. All immunoprecipitations were performed with and without competition of binding using unlabeled insulin, as per the classical IAA RBA protocol. Our results show that the HUI018 mAb specifically bound to all constructs and that the C-peptide was correctly removed from the insulin antigens (ESM Fig. 1a-b). Prolonged storage of the antigens at -80°C, did not affect significantly luciferase activity or antibody binding up to 10 months post freezing (ESM Fig. 2). Five constructs were selected for further analysis in LIPS using human sera: sNLuc proinsulin, B chain-NLuc proinsulin, B chain-NLuc insulin, NLuc-A chain proinsulin, NLuc-A chain insulin.

Performance in LIPS of alternative (pro)insulin luciferases

We conducted a preliminary evaluation of performance in LIPS of the selected (pro)insulin-luciferases using 5 µL of serum per replicate, competition with unlabeled insulin, and 48 hours incubation. All the antigens discriminated in LIPS newly diagnosed T1D (n=76) from control (n=81) sera, albeit with variable efficiency as measured by the analysis of the area under the ROC curve (ROC-AUC) (ESM Fig. 3a-b). Two constructs, in which the NLuc reporter was joined at the COOH terminus of the B chain and preceding the C-peptide (B chain-NLuc proinsulin and B chain-NLuc insulin), were selected for further study.

The B chain-NLuc proinsulin LIPS was then used to test FDRs from the BOX family study [25] that included high risk subjects (n=15), who either developed T1D or tested positive for multiple T1D autoantibodies, and low risk subjects, who tested negative for other T1D autoantibodies and were either positive (n=18) or negative (n=20) for IAA in RBA (Fig. 2). The threshold for positivity was placed at the 97.5th percentile of AU measured by LIPS in serum samples from 186 healthy schoolchildren for both LIPS and RBA. The B chain-NLuc proinsulin LIPS showed a ROC-AUC of 0.877 (95% c.i. 0.762 to 0.993, $p < 0.0001$) compared to 0.774 for RBA (95% c.i. 0.648 to 0.899, $p = 0.002$). While the two ROC-AUCs were not statistically different ($p = 0.214$), a comparison of ROC-AUCs at a specificity greater than 90% showed a trend towards significance in this limited sample set ($p = 0.088$) (ESM Fig. 4).

In blind evaluation of IAA LIPS assays in IASP workshops

The B chain-NLuc proinsulin and insulin LIPS assays performance was verified by testing independently in two laboratories sets of coded human sera obtained from the IASP2015 and

IASP2016 workshops. Both laboratories achieved for the B chain-NLuc proinsulin LIPS an adjusted sensitivity at 95% specificity (AS95) of 64%, ranking first of the 23 IAA assays that reported results for the 2015 workshop, and an AS95 of 50% and 47.9%, ranking third and fourth of the 25 assays reporting results in the IASP2016. The B chain-NLuc insulin LIPS showed an AS95 of 64% in IASP2015, again at the first rank of all assays in that workshop, and of 50% and 43.7% in IASP2016, at the third and sixth rank of all assays in the 2016 workshop.

The concordance of the B chain-NLuc proinsulin LIPS between the two laboratories was high, both as raw data in LU (Spearman $r = 0.967$, $p < 0.0001$ in T1D samples; Spearman $r = 0.618$ $p < 0.0001$ in control samples) and in AU (Spearman $r = 0.974$, $p < 0.0001$ in T1D samples; $r = 0.541$ $p < 0.0001$ in controls) (ESM Fig. 5). In addition, a variety of experimental conditions, including reduced serum volume and assay incubation lengths were evaluated, showing that a comparable assay performance could be achieved by using only 2 μ L of serum and shortening the assay incubation to 18 hours (ESM Fig. 6).

Optimized B chain-NLuc (pro)insulin LIPS performance

Optimized LIPS assays using 2 μ L of serum per replicate and 24 hours incubation were evaluated in new onset T1D ($n=80$) and control ($n=123$) samples. The proinsulin LIPS showed a ROC-AUC of 0.894 (95% c.i. 0.841 to 0.946, $p < 0.0001$), while the insulin LIPS showed a ROC-AUC of 0.916 (95% c.i. 0.872 to 0.960, $p < 0.0001$) (Fig. 3). The results in T1D sera were highly correlated between LIPS assays (Spearman $r = 0.978$, 95% c.i. 0.965 to 0.986, $p < 0.0001$) and between LIPS assays and RBA (B chain-NLuc proinsulin: Spearman $r = 0.866$, 95% c.i. 0.779 to 0.921, $p < 0.0001$; B chain-NLuc insulin: $r = 0.833$, 95% c.i. 0.726 to 0.901, $p < 0.0001$) (ESM Fig. 7).

B chain-NLuc proinsulin LIPS performance in FDRs

The optimized B chain-NLuc proinsulin LIPS assay was used to test in blind 136 FDRs from the BDR family study [26] and its results compared to those of RBA. For both tests the threshold for positivity was placed at the 99th percentile of control titers. The Kaplan-Meier analysis highlighted a different rate of progression to T1D in FDRs IAA positive in LIPS ($n=43$) with a diabetes free survival fraction at 225 months of follow-up of 47%, compared to 79% in the IAA negatives ($n=93$) (Mantel-Haenszel Log rank test $p < 0.0001$) (Fig. 4a). Diabetes free survival at 240 months was 59.6% in the IAA positives in RBA ($n=44$), compared to 74% in IAA negatives ($n=92$) (Mantel-Haenszel Log rank test $p=0.0804$) (Fig. 4b). After grouping according to the concordance

of LIPS and RBA results, the diabetes free survival fraction in FDRs at 181 months was 40% in subjects positive both in LIPS and RBA, 48% in subjects positive only in LIPS, 90% in the subjects that tested IAA positive only in RBA, and 78% in subjects negative for both assays (Fig. 4c).

All FDRs who tested IAA positive exclusively in LIPS (n=9) also had additional T1D associated autoantibodies (5 subjects with single additional GADA and 4 with multiple autoAbs). During follow-up, progression to T1D was observed in 5 subjects of the 9 IAA positive only in LIPS (1 with a single GADA and in all 4 with multiple autoAbs). Conversely, among the 10 FDRs who tested IAA positive exclusively in RBA, additional antibodies were found in only 4 subjects (2 single GADA, 1 single IA-2A, and 1 single ZnT8A positive) of which only one progressed to T1D at a later stage. After stratification of the FDRs according to the presence of other T1D autoantibodies (0 to 3 additional autoAbs), the impact on T1D free survival of IAA positivity in either LIPS or RBA did not reach statistical significance in any of the four grouping categories (ESM Fig. 8).

Discussion

In this study, we developed novel recombinant (pro)insulins tagged with a luciferase reporter and evaluated their performance as antigens for measuring IAA in LIPS, an immunoassay already successfully applied to the measurement of other T1D associated autoantibodies [19–24].

Past studies led to the production of numerous variants of recombinant (pro)insulin proteins, however, we are aware of only two instances in which large GFP or firefly luciferase reporters were fused either within the C-peptide or at the carboxyl terminus of the proinsulin sequence [34, 35]. In both cases, the secretion of mature insulin from cells transfected with these tagged proinsulins could be confirmed, but was nevertheless associated with substantial misfolding and retention in the endoplasmic reticulum.

Initially, our work focused on the generation of (pro)insulins joined to NLuc [36], the smallest commercially available luciferase, and on the systematic analysis of parameters that could potentially affect IAA binding to NLuc-(pro)insulins, including the placement of the reporter relative to the antigen sequence. Our results indicate that, despite the NLuc relatively large size compared to proinsulin, NLuc-(pro)insulins are constitutively secreted by transfected eukaryotic cells and undergo post-translational modifications, including the removal of the C-peptide. More

1
2
3
4 importantly, the engineered (pro)insulins appear to be at least partly correctly folded, an essential
5 requirement for their use in assays measuring IAA [9], as implicitly demonstrated by their
6 recognition, albeit with variable efficiency and background levels, by both monoclonal or human
7 serum antibodies directed against conformational epitopes.
8
9

10
11 We selected two recombinant proteins in which NLuc was joined at the carboxyl terminus of the
12 insulin B chain (B chain-NLuc proinsulin and B chain-NLuc insulin, respectively) as the most
13 promising antigens for IAA measurement in LIPS. We further confirmed the ability of our IAA
14 LIPS to discriminate cases from controls by testing *in blind* new onset T1D and blood donor sera
15 distributed in IASP2015 and IASP2016, the most recent NIDDK sponsored workshops for the
16 standardization of islet autoantibodies [13] and achieve a performance on a par with the best IAA
17 assays that participated in the two workshops.
18
19
20
21
22
23
24

25 Overall, the comparison of LIPS and RBA results, showed a high degree of correlation between
26 the two tests, suggesting that the IAA responses measured by LIPS in new onset T1D patients are
27 mostly consistent with those in obtained by RBA. Furthermore, our preliminary results in a
28 selection of FDRs from the BOX study [25] and from the BDR [26] suggested that LIPS might be
29 more sensitive and specific when used to discriminate future progressors to T1D from subjects
30 with lower risk. However, while in isolation the IAA LIPS showed an advantage over RBA, our
31 study was not sufficiently powered to clarify whether there might be an added benefit of IAA
32 measurement by LIPS in discriminating progressors from non-progressors in the context of
33 strategies based on multiple autoantibody testing. Similar to previous validation studies [18], only
34 the testing of very large cohorts of subjects at risk of T1D will allow the superiority of the IAA
35 LIPS assay over RBA for prediction of T1D, particularly in young children, to be confirmed.
36
37
38
39
40
41
42
43
44
45

46 Compared to RBA, LIPS offers several practical advantages, primarily in the avoidance of
47 radiolabeled tracers, in itself a major source of RBA variability and complexity, because of the
48 short life of ¹²⁵I-insulin and the cumbersome and expensive requirements linked to the use of
49 radioactive substances. In addition to using a non-radioactive tracer with a potentially very long
50 half-life, LIPS offers a greatly shortened assay duration and requires less than half the amount of
51 serum (2 µL vs 5-30 µL per replicate), a noteworthy advantage when IAA testing is performed on
52 precious and essentially irreplaceable archival samples collected for T1D natural history studies
53
54
55
56
57
58
59
60
61
62
63
64
65

[37–40], or from capillary blood samples increasingly used for general population screening [6, 41].

Compared to ECL, another novel non-radioactive immunoassay and currently the only other successfully validated IAA assay format [15, 18], the IAA LIPS offers the benefit of reduced serum consumption, relies on relatively inexpensive and widely available equipment and commercial reagents, and is amenable to future implementation on more advanced micro-fluidic platforms [42, 43].

In conclusion, we have established a novel non-radioactive IAA test that offers high performance while preserving an assay procedure overall similar to the gold standard IAA RBA. This suggests that the IAA LIPS might become an easily transferable replacement for tests based on radiolabeled antigen that might find wide application in the study of the IAA response in T1D.

Conflict of interest

The authors declare that they have no conflict of interest.

Statement of Human and Animal Rights

All procedures followed were in accordance with the ethical standards of the responsible committee on human experimentation (institutional and national) and with the Helsinki Declaration of 1975, as revised in 2008 (5).

Informed consent was obtained from all patients for being included in the study.

References

1. Palmer J, Asplin C, Clemons P, Lyen K, Tatpati O, Raghu P, Paquette T (1983) Insulin antibodies in insulin-dependent diabetics before insulin treatment. *Science* (80-) 222:1337–1339. doi: 10.1126/science.6362005
2. Krischer JP, Lynch KF, Schatz DA, Ilonen J, Lernmark Å, Hagopian WA, Rewers MJ, She J-X, Simell OG, Toppari J, Ziegler A-G, Akolkar B, Bonifacio E, TEDDY Study Group (2015) The 6 year incidence of diabetes-associated autoantibodies in genetically at-risk

- children: the TEDDY study. *Diabetologia* 58:980–7. doi: 10.1007/s00125-015-3514-y
3. Ziegler AG, Hillebrand B, Rabl W, Mayrhofer M, Hummel M, Mollenhauer U, Vordemann J, Lenz A, Standl E (1993) On the appearance of islet associated autoimmunity in offspring of diabetic mothers: a prospective study from birth. *Diabetologia* 36:402–8.
 4. TEDDY Study Group (2007) The Environmental Determinants of Diabetes in the Young (TEDDY) study: study design. *Pediatr Diabetes* 8:286–98. doi: 10.1111/j.1399-5448.2007.00269.x
 5. Kupila A, Muona P, Simell T, Arvilommi P, Savolainen H, Hämäläinen AM, Korhonen S, Kimpimäki T, Sjööros M, Ilonen J, Knip M, Simell O, Juvenile Diabetes Research Foundation Centre for the Prevention of Type I Diabetes in Finland (2001) Feasibility of genetic and immunological prediction of type I diabetes in a population-based birth cohort. *Diabetologia* 44:290–7.
 6. Mahon JL, Sosenko JM, Rafkin-Mervis L, Krause-Steinrauf H, Lachin JM, Thompson C, Bingley PJ, Bonifacio E, Palmer JP, Eisenbarth GS, Wolfsdorf J, Skyler JS, TrialNet Natural History Committee, Type 1 Diabetes TrialNet Study Group (2009) The TrialNet Natural History Study of the Development of Type 1 Diabetes: objectives, design, and initial results. *Pediatr Diabetes* 10:97–104. doi: 10.1111/j.1399-5448.2008.00464.x
 7. Williams AJ, Bingley PJ, Bonifacio E, Palmer JP, Gale EA (1997) A novel micro-assay for insulin autoantibodies. *J Autoimmun* 10:473–8. doi: 10.1006/jaut.1997.0154
 8. Naserke HE, Dozio N, Ziegler AG, Bonifacio E (1998) Comparison of a novel micro-assay for insulin autoantibodies with the conventional radiobinding assay. *Diabetologia* 41:681–3. doi: 9662050
 9. Greenbaum CJ, Palmer JP, Kuglin B, Kolb H (1992) Insulin autoantibodies measured by radioimmunoassay methodology are more related to insulin-dependent diabetes mellitus than those measured by enzyme-linked immunosorbent assay: results of the Fourth International Workshop on the Standardization of Insuli. *J Clin Endocrinol Metab* 74:1040–4. doi: 10.1210/jcem.74.5.1569152
 10. Achenbach P, Schlosser M, Williams AJK, Yu L, Mueller PW, Bingley PJ, Bonifacio E

- (2007) Combined testing of antibody titer and affinity improves insulin autoantibody measurement: Diabetes Antibody Standardization Program. *Clin Immunol* 122:85–90. doi: 10.1016/j.clim.2006.09.004
11. Curnock RM, Reed CR, Rokni S, Broadhurst JW, Bingley PJ, Williams AJK (2012) 'Insulin autoantibody affinity measurement using a single concentration of unlabelled insulin competitor discriminates risk in relatives of patients with type 1 diabetes. *Clin Exp Immunol* 167:67–72. doi: 10.1111/j.1365-2249.2011.04495.x
 12. Williams AJK, Norcross AJ, Chandler KA, Bingley PJ (2006) Non-specific binding to protein A Sepharose and protein G Sepharose in insulin autoantibody assays may be reduced by pre-treatment with glycine or ethanolamine. *J Immunol Methods* 314:170–3. doi: 10.1016/j.jim.2006.06.003
 13. Schlosser M, Mueller PW, Törn C, Bonifacio E, Bingley PJ (2010) Diabetes Antibody Standardization Program: evaluation of assays for insulin autoantibodies. *Diabetologia* 53:2611–20. doi: 10.1007/s00125-010-1915-5
 14. Steck AK, Vehik K, Bonifacio E, Lernmark A, Ziegler A-G, Hagopian WA, She J, Simell O, Akolkar B, Krischer J, Schatz D, Rewers MJ, TEDDY Study Group (2015) Predictors of Progression From the Appearance of Islet Autoantibodies to Early Childhood Diabetes: The Environmental Determinants of Diabetes in the Young (TEDDY). *Diabetes Care* 38:808–13. doi: 10.2337/dc14-2426
 15. Yu L, Miao D, Scrimgeour L, Johnson K, Rewers M, Eisenbarth GS (2012) Distinguishing persistent insulin autoantibodies with differential risk: nonradioactive bivalent proinsulin/insulin autoantibody assay. *Diabetes* 61:179–86. doi: 10.2337/db11-0670
 16. Miao D, Steck AK, Zhang L, Guyer KM, Jiang L, Armstrong T, Muller SM, Krischer J, Rewers M, Yu L, Type 1 Diabetes TrialNet Study Group (2015) Electrochemiluminescence assays for insulin and glutamic acid decarboxylase autoantibodies improve prediction of type 1 diabetes risk. *Diabetes Technol Ther* 17:119–27. doi: 10.1089/dia.2014.0186
 17. Kikkas I, Mallone R, Tubiana-Rufi N, Chevenne D, Carel JC, Créminon C, Volland H, Boitard C, Morel N (2013) A simple and fast non-radioactive bridging immunoassay for

- insulin autoantibodies. PLoS One 8:e69021. doi: 10.1371/journal.pone.0069021
18. Fouts A, Pyle L, Yu L, Miao D, Michels A, Krischer J, Sosenko J, Gottlieb P, Steck AK, Type 1 Diabetes TrialNet Study Group (2016) Do Electrochemiluminescence Assays Improve Prediction of Time to Type 1 Diabetes in Autoantibody-Positive TrialNet Subjects? Diabetes Care 39:1738–44. doi: 10.2337/dc16-0302
 19. Burbelo PD, Kisailus AE, Peck JW (2002) Detecting protein-protein interactions using Renilla luciferase fusion proteins. Biotechniques 33:1044–8, 1050. doi: 12449382
 20. Burbelo PD, Goldman R, Mattson TL (2005) A simplified immunoprecipitation method for quantitatively measuring antibody responses in clinical sera samples by using mammalian-produced Renilla luciferase-antigen fusion proteins. BMC Biotechnol 5:22. doi: 1472-6750-5-22
 21. Burbelo PD, Groot S, Dalakas MC, Iadarola MJ (2008) High definition profiling of autoantibodies to glutamic acid decarboxylases GAD65/GAD67 in stiff-person syndrome. Biochem Biophys Res Commun 366:1–7. doi: S0006-291X(07)02397-2
 22. Burbelo PD, Hirai H, Leahy H, Lernmark A, Ivarsson SA, Iadarola MJ, Louis Notkins A (2008) A New Luminescence Assay for Autoantibodies to Mammalian Cell–Prepared Insulinoma-Associated Protein 2. Diabetes Care 31:1824–1826. doi: 10.2337/dc08-0286
 23. Lampasona V, Passerini L, Barzaghi F, Lombardoni C, Bazzigaluppi E, Brigatti C, Bacchetta R, Bosi E (2013) Autoantibodies to harmonin and villin are diagnostic markers in children with IPEX syndrome. PLoS One 8:e78664. doi: 10.1371/journal.pone.0078664
 24. McLaughlin KA, Richardson CC, Ravishankar A, Brigatti C, Liberati D, Lampasona V, Piemonti L, Morgan D, Feltbower RG, Christie MR (2016) Identification of Tetraspanin-7 as a Target of Autoantibodies in Type 1 Diabetes. Diabetes 65:1690–8. doi: 10.2337/db15-1058
 25. Bingley PJ, Gale EA (1989) Incidence of insulin dependent diabetes in England: a study in the Oxford region, 1985-6. BMJ 298:558–60.
 26. Gorus FK, Balti E V., Messaoui A, Demeester S, Van Dalem A, Costa O, Dorchy H, Mathieu C, Van Gaal L, Keymeulen B, Pipeleers DG, Weets I, Belgian Diabetes Registry

- (2017) Twenty-Year Progression Rate to Clinical Onset According to Autoantibody Profile, Age, and HLA-DQ Genotype in a Registry-Based Group of Children and Adults With a First-Degree Relative With Type 1 Diabetes. *Diabetes Care* 40:1065–1072. doi: 10.2337/dc16-2228
27. Groskreutz DJ, Sliwkowski MX, Gorman CM (1994) Genetically engineered proinsulin constitutively processed and secreted as mature, active insulin. *J Biol Chem* 269:6241–5.
 28. Shaw J a M, Delday MI, Hart a. W, Docherty HM, Maltin C a., Docherty K (2002) Secretion of bioactive human insulin following plasmid-mediated gene transfer to non-neuroendocrine cell lines, primary cultures and rat skeletal muscle in vivo. *J Endocrinol* 172:653–672. doi: 10.1677/joe.0.1720653
 29. Auricchio a, Gao G-P, Yu QC, Raper S, Rivera VM, Clackson T, Wilson JM (2002) Constitutive and regulated expression of processed insulin following in vivo hepatic gene transfer. *Gene Ther* 9:963–71. doi: 10.1038/sj.gt.3301746
 30. Andersen L, Dinesen B, Jørgensen PN, Poulsen F, Røder ME (1993) Enzyme immunoassay for intact human insulin in serum or plasma. *Clin Chem* 39:578–82.
 31. Hilgert I, Stolba P, Kristofová H, Stefanová I, Bendlová B, Lebl M, Horejsí V (1991) A monoclonal antibody applicable for determination of C-peptide of human proinsulin by RIA. *Hybridoma* 10:379–86.
 32. Robin X, Turck N, Hainard A, Tiberti N, Lisacek F, Sanchez J-C, Müller M (2011) pROC: an open-source package for R and S+ to analyze and compare ROC curves. *BMC Bioinformatics* 12:77. doi: 10.1186/1471-2105-12-77
 33. R Development Core Team, r (2005) R: A language and environment for statistical computing. Vienna, Austria
 34. Pouli a E, Kennedy HJ, Schofield JG, Rutter G a (1998) Insulin targeting to the regulated secretory pathway after fusion with green fluorescent protein and firefly luciferase. *Biochem J* 331 (Pt 2:669–75.
 35. Liu M, Hodish I, Rhodes CJ, Arvan P (2007) Proinsulin maturation, misfolding, and proteotoxicity. *Proc Natl Acad Sci U S A* 104:15841–6. doi: 10.1073/pnas.0702697104

- 1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
61
62
63
64
65
36. Hall MP, Unch J, Binkowski BF, Valley MP, Butler BL, Wood MG, Otto P, Zimmerman K, Vidugiris G, Machleidt T, Robers MB, Benink HA, Eggers CT, Slater MR, Meisenheimer PL, Klaubert DH, Fan F, Encell LP, Wood K V. (2012) Engineered luciferase reporter from a deep sea shrimp utilizing a novel imidazopyrazinone substrate. *ACS Chem Biol* 7:1848–57. doi: 10.1021/cb3002478
37. Barker JM, Barriga KJ, Yu L, Miao D, Erlich HA, Norris JM, Eisenbarth GS, Rewers M, Diabetes Autoimmunity Study in the Young (2004) Prediction of autoantibody positivity and progression to type 1 diabetes: Diabetes Autoimmunity Study in the Young (DAISY). *J Clin Endocrinol Metab* 89:3896–902. doi: 10.1210/jc.2003-031887
38. Ziegler AG, Rewers M, Simell O, Simell T, Lempainen J, Steck A, Winkler C, Ilonen J, Veijola R, Knip M, Bonifacio E, Eisenbarth GS (2013) Seroconversion to multiple islet autoantibodies and risk of progression to diabetes in children. *JAMA* 309:2473–9. doi: 10.1001/jama.2013.6285
39. Parikka V, Nääntö-Salonen K, Saarinen M, Simell T, Ilonen J, Hyöty H, Veijola R, Knip M, Simell O (2012) Early seroconversion and rapidly increasing autoantibody concentrations predict prepubertal manifestation of type 1 diabetes in children at genetic risk. *Diabetologia* 55:1926–36. doi: 10.1007/s00125-012-2523-3
40. TEDDY Study Group (2008) The Environmental Determinants of Diabetes in the Young (TEDDY) Study. *Ann N Y Acad Sci* 1150:1–13. doi: 10.1196/annals.1447.062
41. Raab J, Haupt F, Scholz M, Matzke C, Warncke K, Lange K, Assfalg R, Weininger K, Wittich S, Löbner S, Beyerlein A, Nennstiel-Ratzel U, Lang M, Laub O, Dunstheimer D, Bonifacio E, Achenbach P, Winkler C, Ziegler A-G (2016) Capillary blood islet autoantibody screening for identifying pre-type 1 diabetes in the general population: design and initial results of the Fr1da study. *BMJ Open* 6:e011144. doi: 10.1136/bmjopen-2016-011144
42. Zubair A, Burbelo PD, Vincent LG, Iadarola MJ, Smith PD, Morgan NY (2011) Microfluidic LIPS for serum antibody detection: demonstration of a rapid test for HSV-2 infection. *Biomed Microdevices*. doi: 10.1007/s10544-011-9575-x

- 1
2
3
4 43. Burbelo PD, Gunti S, Keller JM, Morse CG, Deeks SG, Lionakis MS, Kapoor A, Li Q,
5
6 Cohen JI, Notkins AL, Alevizos I (2017) Ultrarapid Measurement of Diagnostic Antibodies
7
8 by Magnetic Capture of Immune Complexes. Sci Rep 7:3818. doi: 10.1038/s41598-017-
9
10 03786-7
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
61
62
63
64
65

Figure Legends

Fig. 1 Schematic representation of recombinant luciferase tagged (pro)insulin antigens showing the placement of the NLuc reporter (black arrows) relative to the insulin B chain (white arrows) A chain (grey arrows) and C-peptide (black line). Dashed lines indicate the mutagenesis of recognition sites for native PC1/PC2 convertase to those of furin proteases

Fig. 2 B chain-NLuc proinsulin LIPS results (clear symbols) compared to RBA (grey symbols) in progressors/high-risk (diamonds n=15) and non-progressors/low risk (pointed circles n=38) FDRs from the BOX study (dotted and dashed lines indicate the thresholds for positivity of RBA and LIPS placed at the 97.5th percentile of titers 186 non-diabetic schoolchild shown as clear circles)

Fig. 3 ROC curve analysis of optimized B chain-NLuc proinsulin (black line) or B chain-NLuc insulin (grey line) LIPS performance in a cohort of new onset T1D (n=80) and control (n=123) samples (the dotted line represents the identity line)

Fig. 4 Diabetes-free survival in 136 FDRs from the BDR study tested in the B chain-NLuc proinsulin LIPS (panel a) or RBA (panel b) or stratified according to presence or absence of IAA in both assays (panel c) on the graphs are shown the number of progressors and the total number of subjects in each group and the p value of the Mantel-Haenszel Log-Rank test

Figure 1

Figure 2

Figure 3

Figure 4

SPRINGER NATURE

Disclosure of potential conflicts of interest

Authors must disclose all relationships or interests that could have direct or potential influence or impart bias on the work. Although an author may not feel there is any conflict, disclosure of all relationships and interests provides a more complete and transparent process, leading to an accurate and objective assessment of the work. Awareness of real or perceived conflicts of interest is a perspective to which the readers are entitled. This is not meant to imply that a financial relationship with an organization that sponsored the research or compensation received for consultancy work is inappropriate. For examples of potential conflicts of interests *that are directly or indirectly related to the research* please visit:

www.springer.com/gp/authors-editors/journal-author/journal-author-helpdesk/publishing-ethics/14214

Corresponding authors of papers submitted to Acta Diabetologica
[include name of journal] must complete this form and disclose any real or perceived conflict of interest. The corresponding author signs on behalf of all authors.

The corresponding author will include a statement in that reflects what is recorded in the potential conflict of interest disclosure form. Please check the Instructions for Authors where to put the statement which may be different dependent on the type of peer review used for the journal. Please note that you cannot save the form once completed. Please print upon completion, sign, and scan to keep a copy for your files.

The corresponding author should be prepared to send the potential conflict of interest disclosure form if requested during peer review or after publication on behalf of all authors (if applicable).

☒ We have no potential conflict of interest.

Category of disclosure	Description of Interest/Arrangement

Article title A novel LIPS assay for insulin autoantibodies

Manuscript No. (if you know it) _____

Corresponding author name Vito Lampasona

Herewith I confirm, on behalf of all authors, that the information provided is accurate.

Author signature Date 6th October 2017